Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis

  title={Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis},
  author={Evangelos C. Rizos and Georgios Markozannes and Apostolos Tsapas and Christos S. Mantzoros and Evangelia E. Ntzani},
  pages={150 - 158}
Background Omega-3 supplements are popular for cardiovascular disease (CVD) prevention. We aimed to assess the association between dose-specific omega-3 supplementation and CVD outcomes. Design We included double-blind randomised clinical trials with duration ≥1 year assessing omega-3 supplementation and estimated the relative risk (RR) for all-cause mortality, cardiac death, sudden death, myocardial infarction and stroke. Primary analysis was a stratified random-effects meta-analysis by omega… 

Omega-3 Fatty Acid Supplementation and Coronary Heart Disease Risks: A Meta-Analysis of Randomized Controlled Clinical Trials

Omega-3 FA supplementation had a positive effect in reducing the incidence of MACE, cardiovascular death, MI and it was revealed that gender and diabetes have no significant association between omega-3FA supplementation and MACE risk.

Correspondence on ‘Impact of omega-3 supplement on metabolic syndrome and/or Helicobacter pylori-related risk of cardiovascular disease’ by Kountouras et al

It was shown that lowdose omega3 supplementation had no association with CV outcomes with a strong indication that this is unlikely to change over time, and evidence towards no benefit from moderate omega3 doses was provided.

Impact of omega-3 supplement on metabolic syndrome and/or Helicobacter pylori-related risk of cardiovascular disease

There is an association between HpI and MetSrelated morbidity, including cardiocerebrovascular events, and eradication therapy and improvement of Hprelated MetS parameters mainly by omega3 supplements might benefitcardiac disease events and even prevention of certain cancers and thus further studies are warranted.

Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis

PUFA consumption, especially omega-3 from animal source >2 g/day, may improve IRD activity and might be an adjuvant therapy in rheumatoid arthritis.

Omega-3 Fatty Acids Improve Functionality of High-Density Lipoprotein in Individuals With High Cardiovascular Risk: A Randomized, Parallel, Controlled and Double-Blind Clinical Trial

In conclusion, omega-3 was effective in the reduction of cardiovascular risk associated with HDL functionality by size improvement and changes in its lipid, antioxidant and enzyme composition.

Associations among Dietary Omega-3 Polyunsaturated Fatty Acids, the Gut Microbiota, and Intestinal Immunity

Omega-3 supplementation can be targeted to specific pathways to prevent and alleviate intestinal diseases, which may help researchers identify innovative diagnostic methods.

Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?

Omega-3 has little side effects compared to antipsychotics and may be safely prescribed for UHR patients and as an add-on for FEP patients, thus contributing to precision medicine in psychiatry.

Nutritional Enhancement of Health Beneficial Omega-3 Long-Chain Polyunsaturated Fatty Acids in the Muscle, Liver, Kidney, and Heart of Tattykeel Australian White MARGRA Lambs Fed Pellets Fortified with Omega-3 Oil in a Feedlot System

The findings demonstrate that the inclusion of omega-3 oil in feedlot diets of lambs enhances the human health beneficial Omega-3 long-chain polyunsaturated fatty acid profiles of edible muscle tissue and organs without compromising meat quality or shelf life.

Highlighting the latest research: January 2021

A selection of recently published articles of interest to nurses working in cardiovascular nursing are presented and a brief overview of the research is provided.



Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.

Overall, omega-3 PUFA supplementation was not associated with a lower risk of all-cause mortality, cardiac death, sudden death, myocardial infarction, or stroke based on relative and absolute measures of association.

A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk

  • G. EinvikTor Ole KlemsdalL. SandvikE. Hjerkinn
  • Medicine
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
  • 2010
A tendency toward reduction in all-cause mortality in the n-3 PUFA groups reached borderline statistical significance, and the magnitude of risk-reduction suggests that a larger trial should be considered in similar populations.

Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial

This study does not support the routine use of dietary supplements containing B vitamins or omega 3 fatty acids for prevention of cardiovascular disease in people with a history of ischaemic heart disease or ischaemia stroke, at least when supplementation is introduced after the acute phase of the initial event.

n-3 fatty acids and cardiovascular events after myocardial infarction.

Low-dose supplementation with EPA-DHA or ALA did not significantly reduce the rate of major cardiovascular events among patients who had had a myocardial infarction and who were receiving state-of-the-art antihypertensive, antithrombotic, and lipid-modifying therapy.

Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review.

There is low strength of evidence (SoE) of no association between total n-3 FA intake and stroke death or myocardial infarction, and also that higher marine oil intake does not affect major adverse CV events, all-cause death, sudden cardiac death, coronary revascularization, atrial fibrillation, or BP.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events.

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Effect of increased intake of fish- and plant-based omega-3 for all-cause mortality, cardiovascular (CVD) events, adiposity and lipids is assessed and it is suggested that LCn3 probably makes little or no difference to CHD event risk.

OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction

Background— There is no randomized, double-blind trial testing the prognostic effect of highly purified omega-3 fatty acids in addition to current guideline-adjusted treatment of acute myocardial

The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial.

Dietary intake of omega-3 fatty acids modestly mitigates the course of coronary atherosclerosis in humans.

Marine n‐3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer

BACKGROUND Higher intake of marine n‐3 (also called omega‐3) fatty acids has been associated with reduced risks of cardiovascular disease and cancer in several observational studies. Whether